INT214886

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 4.06
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Atcay) mRNA processing (FIP1L1) nucleolus (FIP1L1)
RNA binding (FIP1L1) nucleus (FIP1L1)
Anatomy Link Frequency
stem cell 2
Atcay (Mus musculus)
FIP1L1 (Homo sapiens)
Pain Link Frequency Relevance Heat
corticosteroid 52 5.00 Very Low Very Low Very Low
cytokine 28 5.00 Very Low Very Low Very Low
cva 8 5.00 Very Low Very Low Very Low
fibrosis 8 5.00 Very Low Very Low Very Low
chemokine 8 5.00 Very Low Very Low Very Low
tolerance 6 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
vincristine 4 5.00 Very Low Very Low Very Low
imagery 4 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypereosinophilic Syndrome 252 100.00 Very High Very High Very High
Disease 142 93.72 High High
Hypersensitivity 12 83.92 Quite High
Myeloproliferative Disorder 16 65.48 Quite High
Splenomegaly 12 58.56 Quite High
Anaemia 10 58.00 Quite High
Thrombocytopenia 10 57.44 Quite High
Hyperplasia 2 54.00 Quite High
Myelofibrosis 2 52.08 Quite High
Rhinitis 40 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The following terms are currently used in medical literature to qualify different patient subsets among those fulfilling the diagnostic criteria of HES:

• FIP1L1-PDGFRA(F/P)-associated HES, or F/P+ HES, for patients with clonal hypereosinophilia due to a sporadic hematopoiëtic stem cell chromosomal rearrangement resulting in fusion of two genes (FIP1L1 and PDGFRA) on 4q12; these patients are more appropriately classified as F/P+ chronic eosinophilic leukemia. • Chronic eosinophilic leukemia (CEL), for patients in whom clonality of eosinophils has been demonstrated (including those with the FIP1L1-PDGFRA fusion), or who present increased blasts; occasional reports indicate that some patients with CEL progress towards acute myeloid or eosinophilic leukemia. • Lymphocytic-HES (L-HES), for patients with chronic reactive (polyclonal) hypereosinophilia secondary to IL-5 over-production by T cells. • Myeloproliferative-HES (M-HES) may be used for patients with an array of clinical and biological features suggesting the possible existence of an underlying myeloproliferative disorder associated with hypereosinophilia, although underlying molecular defects are not detected (including increased serum vitamin B12, hepato- and/or splenomegaly, anemia and/or thrombocytopenia, circulating myeloid precursors, dysplastic eosinophils, bone marrow hypercellularity with left shift in maturation, myelofibrosis, increased serum tryptase, and response to imatinib); this term is occasionally extended more largely to include patients with known molecular defects (e.g.

HES Binding (associated) of FIP1L1 in stem cell associated with myeloproliferative disorder, anaemia, splenomegaly, hypereosinophilic syndrome, thrombocytopenia, myelofibrosis and hyperplasia
1) Confidence 0.08 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC2045078 Disease Relevance 2.03 Pain Relevance 0
The following terms are currently used in medical literature to qualify different patient subsets among those fulfilling the diagnostic criteria of HES:

• FIP1L1-PDGFRA(F/P)-associated HES, or F/P+ HES, for patients with clonal hypereosinophilia due to a sporadic hematopoiëtic stem cell chromosomal rearrangement resulting in fusion of two genes (FIP1L1 and PDGFRA) on 4q12; these patients are more appropriately classified as F/P+ chronic eosinophilic leukemia. • Chronic eosinophilic leukemia (CEL), for patients in whom clonality of eosinophils has been demonstrated (including those with the FIP1L1-PDGFRA fusion), or who present increased blasts; occasional reports indicate that some patients with CEL progress towards acute myeloid or eosinophilic leukemia. • Lymphocytic-HES (L-HES), for patients with chronic reactive (polyclonal) hypereosinophilia secondary to IL-5 over-production by T cells. • Myeloproliferative-HES (M-HES) may be used for patients with an array of clinical and biological features suggesting the possible existence of an underlying myeloproliferative disorder associated with hypereosinophilia, although underlying molecular defects are not detected (including increased serum vitamin B12, hepato- and/or splenomegaly, anemia and/or thrombocytopenia, circulating myeloid precursors, dysplastic eosinophils, bone marrow hypercellularity with left shift in maturation, myelofibrosis, increased serum tryptase, and response to imatinib); this term is occasionally extended more largely to include patients with known molecular defects (e.g.

HES Binding (associated) of FIP1L1 in stem cell associated with myeloproliferative disorder, anaemia, splenomegaly, hypereosinophilic syndrome, thrombocytopenia, myelofibrosis and hyperplasia
2) Confidence 0.08 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC2045078 Disease Relevance 2.02 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox